Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation

Joseph L. Blackshear, Miguel Zabalgoitia, Gregory Pennock, Paul Fenster, Richard Strauss, Jonathan Halperin, Richard Asinger, Lesly A. Pearce

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Abstract

Patients with atrial fibrillation and with documented oartic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0) had an annual rate of cholesterol embolization of 0.7% (95% confidence interval [CI] 0.1% to 5.3%/patient-year). Warfarin-assigned patients with plaque had a lower rate of embolic events (5.9%/year; 95% CI 3.0 to 12) than those on combination low-dose warfarin (international normalized ratio <1.5) plus aspirin (17.3%/year; 95% CI 11 to 27; p = 0.01).

Original languageEnglish
Pages (from-to)453-455
Number of pages3
JournalAmerican Journal of Cardiology
Volume83
Issue number3
DOIs
StatePublished - 1 Feb 1999

Fingerprint

Dive into the research topics of 'Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation'. Together they form a unique fingerprint.

Cite this